HUTCHMED China Ltd (HCM) - Total Liabilities
Based on the latest financial reports, HUTCHMED China Ltd (HCM) has total liabilities worth GBX501.83 Million GBX (≈ $61.06K USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore HUTCHMED China Ltd annual equity growth to track the company's year-over-year net asset growth rate.
HUTCHMED China Ltd - Total Liabilities Trend (2005–2025)
This chart illustrates how HUTCHMED China Ltd's total liabilities have evolved over time, based on quarterly financial data. See cash generation quality of HUTCHMED China Ltd to measure how efficiently the company converts operating cash flow to free cash.
HUTCHMED China Ltd Competitors by Total Liabilities
The table below lists competitors of HUTCHMED China Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Astral Asia Bhd
KLSE:7054
|
Malaysia | RM106.03 Million |
|
New Zealand Energy Corp
V:NZ
|
Canada | CA$11.73 Million |
|
Job Solution Sweden Holding AB
ST:JOBS
|
Sweden | Skr172.48 Million |
|
Greenwing Resources Ltd
AU:GW1
|
Australia | AU$4.50 Million |
|
Trilogiq
PA:ALTRI
|
France | €3.75 Million |
|
Pungkang Co. Ltd
KQ:093380
|
Korea | ₩22.17 Billion |
|
Keyware Technologies NV
BR:KEYW
|
Belgium | €7.26 Million |
|
Polylite Taiwan Co Ltd
TWO:1813
|
Taiwan | NT$314.57 Million |
Liability Composition Analysis (2005–2025)
This chart breaks down HUTCHMED China Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see HUTCHMED China Ltd market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.96 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.41 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.29 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how HUTCHMED China Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for HUTCHMED China Ltd (2005–2025)
The table below shows the annual total liabilities of HUTCHMED China Ltd from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | GBX501.15 Million ≈ $60.98K |
-0.24% |
| 2024-12-31 | GBX502.34 Million ≈ $61.12K |
-6.35% |
| 2023-12-31 | GBX536.39 Million ≈ $65.26K |
+36.63% |
| 2022-12-31 | GBX392.57 Million ≈ $47.77K |
+17.84% |
| 2021-12-31 | GBX333.15 Million ≈ $40.53K |
+62.38% |
| 2020-12-31 | GBX205.17 Million ≈ $24.96K |
+34.79% |
| 2019-12-31 | GBX152.22 Million ≈ $18.52K |
+26.99% |
| 2018-12-31 | GBX119.86 Million ≈ $14.58K |
+6.11% |
| 2017-12-31 | GBX112.97 Million ≈ $13.74K |
-18.36% |
| 2016-12-31 | GBX138.38 Million ≈ $16.84K |
+8.55% |
| 2015-12-31 | GBX127.48 Million ≈ $15.51K |
+28.69% |
| 2014-12-31 | GBX99.06 Million ≈ $12.05K |
+22.55% |
| 2013-12-31 | GBX80.83 Million ≈ $9.83K |
-35.76% |
| 2012-12-31 | GBX125.82 Million ≈ $15.31K |
+7.13% |
| 2011-12-31 | GBX117.44 Million ≈ $14.29K |
+28.89% |
| 2010-12-31 | GBX91.12 Million ≈ $11.09K |
+73.71% |
| 2009-12-31 | GBX52.45 Million ≈ $6.38K |
+56.43% |
| 2008-12-31 | GBX33.53 Million ≈ $4.08K |
+11.93% |
| 2007-12-31 | GBX29.96 Million ≈ $3.64K |
+29.89% |
| 2006-12-31 | GBX23.06 Million ≈ $2.81K |
-74.63% |
| 2005-12-31 | GBX90.89 Million ≈ $11.06K |
-- |
About HUTCHMED China Ltd
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast c… Read more